Shots:

• Roche reports an exploratory analysis of P-III IMvigor010 study assessing efficacy and safety of adjuvant treatment with Tecentriq vs observation in 809 people with MIUC- who are at high risk of recurrence following resection
• Results: in people with ctDNA- DFS Median (5.9 vs 4.4 mos.); median OS (25.8 vs 15.8 mos.). As presented in ASCO- the study did not meet its 1EPs of DFS (19.4 vs 16.6 mos.) in IIT population
• In general- people with MIUC who had detectable ctDNA were more likely to benefit from treatment with adjuvant Tecentriq monothx. compared with those without ctDNA

 ­ Ref: Roche | Image: Roche